Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

151 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The percentage of Epidermal Growth Factor Receptor (EGFR)-mutated neoplastic cells correlates to response to tyrosine kinase inhibitors in lung adenocarcinoma.
de Biase D, Genestreti G, Visani M, Acquaviva G, Di Battista M, Cavallo G, Paccapelo A, Cancellieri A, Trisolini R, Degli Esposti R, Bartolini S, Pession A, Tallini G, Brandes AA. de Biase D, et al. Among authors: bartolini s. PLoS One. 2017 May 16;12(5):e0177822. doi: 10.1371/journal.pone.0177822. eCollection 2017. PLoS One. 2017. PMID: 28520821 Free PMC article.
Survival prediction in high-grade gliomas using CT perfusion imaging.
Yeung TP, Wang Y, He W, Urbini B, Gafà R, Ulazzi L, Yartsev S, Bauman G, Lee TY, Fainardi E; Project of Emilia-Romagna Region on Neuro-Oncology Study Group. Yeung TP, et al. J Neurooncol. 2015 May;123(1):93-102. doi: 10.1007/s11060-015-1766-5. Epub 2015 Apr 11. J Neurooncol. 2015. PMID: 25862005
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Cappuzzo F, Gregorc V, Rossi E, Cancellieri A, Magrini E, Paties CT, Ceresoli G, Lombardo L, Bartolini S, Calandri C, de Rosa M, Villa E, Crino L. Cappuzzo F, et al. Among authors: bartolini s. J Clin Oncol. 2003 Jul 15;21(14):2658-63. doi: 10.1200/JCO.2003.01.039. J Clin Oncol. 2003. PMID: 12860941 Clinical Trial.
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Cappuzzo F, Magrini E, Ceresoli GL, Bartolini S, Rossi E, Ludovini V, Gregorc V, Ligorio C, Cancellieri A, Damiani S, Spreafico A, Paties CT, Lombardo L, Calandri C, Bellezza G, Tonato M, Crinò L. Cappuzzo F, et al. Among authors: bartolini s. J Natl Cancer Inst. 2004 Aug 4;96(15):1133-41. doi: 10.1093/jnci/djh217. J Natl Cancer Inst. 2004. PMID: 15292385 Clinical Trial.
Perspectives on salvage therapy for non-small-cell lung cancer.
Cappuzzo F, Finocchiaro G, Trisolini R, Toschi L, Bartolini S, Metro G, Crinò L. Cappuzzo F, et al. Among authors: bartolini s. Oncology (Williston Park). 2005 Jul;19(8):989-95; discussion 995-6, 999, 1003-4, passim. Oncology (Williston Park). 2005. PMID: 16131043 Review.
Clinical experience with gefitinib: an update.
Cappuzzo F, Finocchiaro G, Metro G, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L. Cappuzzo F, et al. Among authors: bartolini s. Crit Rev Oncol Hematol. 2006 Apr;58(1):31-45. doi: 10.1016/j.critrevonc.2005.08.008. Epub 2006 Mar 13. Crit Rev Oncol Hematol. 2006. PMID: 16531062 Review.
EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
Cappuzzo F, Ligorio C, Toschi L, Rossi E, Trisolini R, Paioli D, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Hirsch FR, Crino L, Varella-Garcia M. Cappuzzo F, et al. Among authors: bartolini s. J Thorac Oncol. 2007 May;2(5):423-9. doi: 10.1097/01.JTO.0000268676.79872.9b. J Thorac Oncol. 2007. PMID: 17473658 Free article.
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
Cappuzzo F, Ligorio C, Jänne PA, Toschi L, Rossi E, Trisolini R, Paioli D, Holmes AJ, Magrini E, Finocchiaro G, Bartolini S, Cancellieri A, Ciardiello F, Patelli M, Crino L, Varella-Garcia M. Cappuzzo F, et al. Among authors: bartolini s. J Clin Oncol. 2007 Jun 1;25(16):2248-55. doi: 10.1200/JCO.2006.09.4300. J Clin Oncol. 2007. PMID: 17538169 Clinical Trial.
MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. Brandes AA, et al. Among authors: bartolini s. J Clin Oncol. 2008 May 1;26(13):2192-7. doi: 10.1200/JCO.2007.14.8163. J Clin Oncol. 2008. PMID: 18445844
151 results